These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 17845984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD, Lindley C.
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Feb 01; 11(3):982-92. PubMed ID: 15709163
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
    Clin Cancer Res; 2009 Jan 01; 15(1):382-9. PubMed ID: 19118069
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
    Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T.
    Anticancer Res; 2010 Oct 01; 30(10):4309-15. PubMed ID: 21036757
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.
    J Clin Oncol; 2003 Apr 15; 21(8):1556-61. PubMed ID: 12697881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.
    Cancer Treat Rev; 2010 Feb 15; 36(1):24-32. PubMed ID: 19879055
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
    Gridelli C, Di Maio M.
    Expert Opin Pharmacother; 2010 Feb 15; 11(2):321-4. PubMed ID: 20053140
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M, Gatzemeier U.
    Expert Rev Anticancer Ther; 2005 Apr 15; 5(2):231-7. PubMed ID: 15877521
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD, Dragnev KH, Rigas JR.
    Expert Opin Pharmacother; 2010 Jun 15; 11(8):1387-402. PubMed ID: 20446853
    [Abstract] [Full Text] [Related]

  • 20. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M, White RM, Johnson JR, Pazdur R.
    Oncologist; 2004 Jun 15; 9(5):482-8. PubMed ID: 15477632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.